241 related articles for article (PubMed ID: 25494823)
1. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
Trials; 2014 Dec; 15():489. PubMed ID: 25494823
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
[TBL] [Abstract][Full Text] [Related]
3. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
[TBL] [Abstract][Full Text] [Related]
5. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
Sommerer C; Giese T; Meuer S; Zeier M
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
[TBL] [Abstract][Full Text] [Related]
7. Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial.
Sommerer C; Brocke J; Bruckner T; Schaier M; Morath C; Meuer S; Zeier M; Giese T
Transplantation; 2018 Mar; 102(3):510-520. PubMed ID: 29077654
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A.
Sommerer C; Zeier M; Meuer S; Giese T
Clin Nephrol; 2015 Sep; 84(3):165-72. PubMed ID: 26226950
[TBL] [Abstract][Full Text] [Related]
9. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
10. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
[TBL] [Abstract][Full Text] [Related]
12. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
13. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors.
Matsuda Y; Chen F; Miyata H; Date H
Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):171-3. PubMed ID: 24659549
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
16. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
19. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
20. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
